- Home
- AUPH vs DXPE Comparison
AUPH vs DXPE Comparison
Compare AUPH & DXPE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUPH
- DXPE
- Stock Information
- Founded
- AUPH 1993
- DXPE 1908
- Country
- AUPH Canada
- DXPE United States
- Employees
- AUPH 300
- DXPE N/A
- Industry
- AUPH Biotechnology: Pharmaceutical Preparations
- DXPE Industrial Machinery/Components
- Sector
- AUPH Health Care
- DXPE Industrials
- Exchange
- AUPH Nasdaq
- DXPE Nasdaq
- Market Cap
- AUPH 1.2B
- DXPE 1.4B
- IPO Year
- AUPH 1999
- DXPE 1996
- Fundamental
- Price
- AUPH $8.93
- DXPE $108.17
- Analyst Decision
- AUPH Strong Buy
- DXPE Buy
- Analyst Count
- AUPH 2
- DXPE 1
- Target Price
- AUPH $11.50
- DXPE $95.00
- AVG Volume (30 Days)
- AUPH 2.1M
- DXPE 255.3K
- Earning Date
- AUPH 07-31-2025
- DXPE 08-07-2025
- Dividend Yield
- AUPH N/A
- DXPE N/A
- EPS Growth
- AUPH N/A
- DXPE 33.22
- EPS
- AUPH 0.27
- DXPE 4.81
- Revenue
- AUPH $247,295,000.00
- DXPE $1,865,974,000.00
- Revenue This Year
- AUPH $12.15
- DXPE $11.87
- Revenue Next Year
- AUPH $18.34
- DXPE $3.57
- P/E Ratio
- AUPH $33.57
- DXPE $22.51
- Revenue Growth
- AUPH 29.20
- DXPE 11.94
- 52 Week Low
- AUPH $5.20
- DXPE $45.00
- 52 Week High
- AUPH $10.67
- DXPE $108.65
- Technical
- Relative Strength Index (RSI)
- AUPH 57.25
- DXPE 75.49
- Support Level
- AUPH $8.73
- DXPE $97.41
- Resistance Level
- AUPH $9.37
- DXPE $101.86
- Average True Range (ATR)
- AUPH 0.41
- DXPE 4.05
- MACD
- AUPH 0.04
- DXPE 1.11
- Stochastic Oscillator
- AUPH 77.28
- DXPE 97.73
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
About DXPE DXP Enterprises Inc.
DXP Enterprises Inc is a distributor of products and services to industrial customers in the United States, Canada, Mexico, and Dubai. The company's reportable segments include Service Centers, Innovative Pumping Solutions, and Supply Chain Services. It generates maximum revenue from the Service Centers segment. The company offers pumping solutions, supply chain services and maintenance, repair, operating, and production services for rotating equipment, bearings, power transmissions, industrial supplies, and safety products. It serves the General Industrial, Oil & Gas, Food & Beverage, Water & Wastewater, Chemical, Transportation, Aerospace & Others.